HSASingaporeSource updated: Jun 4, 2026

HeartWare Ventricular Assist System Batteries - HSA Field Safety Notice

HSA Singapore issued a Field Safety Notice on June 4, 2026, regarding all HeartWare Ventricular Assist System batteries due to potential performance issues. Manufacturers' battery management and replacement instructions must be followed.

Primary source: HSA

PV Impact Brief

Urgency: HighConfidence: high

What changed

HSA Singapore issued a Field Safety Notice for all HeartWare Ventricular Assist System batteries due to potential performance issues.

Why it matters

Battery performance issues in the HeartWare Ventricular Assist System could lead to device malfunction, posing serious risks to patients reliant on the system for cardiac support.

Relevant for: Regulatory Intelligence LeadSignal Management Lead
Processes impacted: Signal ManagementLabeling
Action needed: Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.
Owner: Regulatory Intelligence Lead
Review cadence: As needed per manufacturer updates or further HSA communications.

Regulatory action details

Action type: Field Safety Notice
Publication date: 2026-06-04
Safety issue: Field safety notice regarding all HeartWare Ventricular Assist System batteries, concerning potential performance issues.

Affected products

HeartWare Ventricular Assist System Batteries

PV internal implications

Healthcare providers and patients should follow the specific battery management and replacement instructions provided by the manufacturer.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 4, 2026

HSA →Updated June 4, 2026

Full briefing

Practical implication

Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.

The Health Sciences Authority (HSA) of Singapore published a Field Safety Notice for HeartWare Ventricular Assist System batteries due to potential performance issues. Healthcare providers and patients are instructed to follow specific battery management and replacement instructions from the manufacturer.

What changed: HSA Singapore issued a Field Safety Notice for all HeartWare Ventricular Assist System batteries due to potential performance issues.

Why it matters: Battery performance issues in the HeartWare Ventricular Assist System could lead to device malfunction, posing serious risks to patients reliant on the system for cardiac support.

Practical implication: Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals #HeartWare #Ventricular Assist System #Battery #Field Safety Notice #HSA #other #firecrawl-agent

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Draft Guidance

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Technical Guidance

Read impact briefarrow_forward

publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV

verifiedRegulatory action: Draft Guidance

Read impact briefarrow_forward